Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


gefitinib resistance ( 40 / 21 /
6
/
13
)
gemcitabine resistance ( 66 / 33 /
11
/
22
)
genomic instability ( 14 / 7 /
3
/
4
)
gluconeogenesis ( 6 / 3 /
1
/
2
)
5fluorouracil resistance ( 144 / 81 /
27
/
36
)
adhesion ( 57 / 31 /
8
/
18
)
Adriamycin (Adr) resistance ( 30 / 16 /
4
/
10
)
aerobic glycolysis ( 87 / 44 /
13
/
30
)
Afatinib resistance ( 2 / 1 /
0
/
1
)
AKT signaling ( 341 / 172 /
57
/
112
)
anchorage-independent growth ( 45 / 23 /
12
/
10
)
Angiogenesis ( 306 / 158 /
52
/
96
)
Anoikis ( 36 / 19 /
9
/
8
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Apoptosis ( 2171 / 1099 /
695
/
377
)
Autophagy ( 498 / 250 /
114
/
134
)
beta-catenin signaling ( 81 / 41 /
14
/
26
)
BMP signaling ( 235 / 127 /
72
/
36
)
Bone metastasis ( 28 / 16 /
4
/
8
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
Brain metastasis ( 2 / 1 /
0
/
1
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
BRCAness ( 2 / 1 /
1
/
0
)
Camptothecin resistance ( 3 / 2 /
0
/
1
)
cancer progression ( 16 / 9 /
5
/
2
)
carboplatin resistance ( 4 / 2 /
1
/
1
)
Castrate Resistance ( 29 / 17 /
9
/
3
)
cell cycle ( 262 / 137 /
46
/
79
)
cell cycle arrest ( 519 / 263 /
228
/
28
)
cell cycle progression ( 193 / 98 /
46
/
49
)
Cell growth ( 902 / 455 /
140
/
307
)
cell polarity ( 1 / 1 /
0
/
0
)
cell spreading ( 8 / 6 /
0
/
2
)
cell viability ( 358 / 183 /
47
/
128
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
Chemoresistance ( 320 / 161 /
62
/
97
)
IFN production ( 10 / 5 /
2
/
3
)
colony formation ( 605 / 308 /
80
/
217
)
differentiation ( 95 / 48 /
31
/
16
)
DNA repair ( 71 / 36 /
25
/
10
)
EMT ( 1097 / 555 /
221
/
321
)
growth ( 222 / 131 /
26
/
65
)
inflammation ( 119 / 60 /
26
/
33
)
Invasion ( 4407 / 2229 /
725
/
1453
)
MET ( 20 / 11 /
9
/
)
Metastasis ( 1341 / 679 /
273
/
389
)
migration ( 3559 / 1795 /
578
/
1186
)
motility ( 221 / 113 /
35
/
73
)
NF-kB signaling ( 265 / 134 /
67
/
64
)
Oxaliplatin ( 2 / 1 /
1
/
)
Oxaliplatin resistance ( 33 / 17 /
7
/
9
)
Paclitaxel resistance ( 75 / 38 /
14
/
23
)
Proliferation ( 5042 / 2541 /
812
/
1689
)
Radioresistance ( 159 / 81 /
30
/
48
)
Senescence ( 75 / 41 /
26
/
8
)
stemness ( 299 / 150 /
71
/
78
)
survival ( 138 / 71 /
24
/
43
)
Tamoxifen resistance ( 25 / 13 /
8
/
4
)
cisplatin resistance ( 404 / 203 /
69
/
132
)
doxorubicin resistance ( 97 / 49 /
15
/
33
)
ERK pathway (MAPK pathway) ( 213 / 107 /
34
/
72
)
etoposide ( 9 / 5 /
3
/
1
)
Liver metastasis ( 30 / 17 /
5
/
8
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
multidrug resistance ( 22 / 12 /
5
/
5
)
RAS signaling pathway ( 10 / 6 /
2
/
2
)
tumor growth ( 1014 / 510 /
176
/
328
)
Lung metastasis ( 79 / 41 /
19
/
19
)
PI3K signaling ( 123 / 62 /
22
/
39
)
WNT signaling ( 436 / 219 /
99
/
118
)
Hedgehog (Hh) signaling ( 38 / 20 /
6
/
12
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
Response to genotoxic stress ( 6 / 4 /
2
/
)
tumor-stroma interactions ( 3 / 2 /
1
/
)
docetaxel resistance ( 55 / 29 /
20
/
6
)
epirubicin resistance ( 5 / 3 /
2
/
)
JAK/STAT signaling ( 122 / 62 /
31
/
29
)
mTOR signaling ( 92 / 46 /
12
/
34
)
Necrosis ( 6 / 3 /
2
/
1
)
NOTCH signaling ( 93 / 47 /
24
/
22
)
P38 signaling ( 39 / 20 /
11
/
8
)
poor prognosis ( 46 / 26 /
17
/
3
)
Transformation ( 15 / 12 /
2
/
1
)
tumor progression ( 82 / 42 /
24
/
16
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
unfolded protein response ( 7 / 5 /
1
/
1
)
Vorinostat Resistance ( 6 / 4 /
2
/
)
cytotoxicity ( 2 / 1 /
1
/
)
lipogenesis ( 25 / 13 /
1
/
11
)
TGF-beta signaling ( 464 / 257 /
105
/
102
)
Temozolomide (TMZ) resistance ( 42 / 21 /
6
/
15
)
Lapatinib resistance ( 6 / 3 /
1
/
2
)
daunorubicin (DNR) Resistance ( 6 / 3 /
2
/
1
)
T cell activation ( 3 / 2 /
1
/
)
Sorafenib resistance ( 42 / 21 /
6
/
15
)
glucose metabolism ( 18 / 9 /
3
/
6
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 34 / 17 /
10
/
7
)
Hippo signaling pathway ( 180 / 90 /
66
/
24
)
fibrosis ( 50 / 25 /
10
/
15
)
MAPK/JNK Signaling Pathway ( 24 / 12 /
5
/
7
)
Hypoxic response ( 14 / 8 /
6
/
)
Taxanes (paclitaxel and docetaxel) resistance ( 22 / 14 /
5
/
3
)
Trastuzumab resistance ( 20 / 10 /
6
/
4
)
TRAIL resistance ( 16 / 8 /
5
/
3
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
pyroptosis ( 16 / 8 /
7
/
1
)
Sunitinib resistance ( 8 / 4 /
4
/
)
Antiviral response ( 13 / 7 /
2
/
4
)
Response to oxidative stress ( 14 / 13 /
1
/
)
tumor-initiating properties ( 9 / 6 /
/
3
)
ER stress ( 32 / 17 /
/
15
)
inflammatory monocyte recruitment ( 4 / 3 /
/
1
)
Imatinib resistance ( 18 / 11 /
/
7
)
NK cell cytotoxicity ( 6 / 4 /
/
2
)
disease-free survival ( 3 / 2 /
/
1
)
EGFR-TKI resistance ( 4 / 3 /
/
1
)
MTX resistance ( 3 / 2 /
/
1
)
Osteolysis ( 5 / 3 /
/
2
)
Neratinib resistance ( 2 / 1 /
/
1
)
Rapamycin resistance ( 2 / 1 /
/
1
)
BCL2 inhibitors resistance ( 2 / 1 /
/
1
)
glycolysis ( 15 / 14 /
/
1
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
erythropoiesis ( 3 / 3 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
macrophage attraction ( 1 / 1 /
0
/
0
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
redox homeostasis ( 3 / 3 /
0
/
0
)
scattering ( 1 / 1 /
0
/
0
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Tyrosine kinase inhibitors (TKIs) resistance ( 1 / 1 /
0
/
0
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)
chondrogenesis ( 1 / 1 /
0
/
0
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)